Vitro Diagnostics (OTCMKTS:VODG) and Vaxart (NASDAQ:VXRT) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, dividends, profitability, valuation, analyst recommendations and institutional ownership.
This is a summary of current recommendations for Vitro Diagnostics and Vaxart, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Insider and Institutional Ownership
4.6% of Vaxart shares are held by institutional investors. 27.7% of Vitro Diagnostics shares are held by company insiders. Comparatively, 7.3% of Vaxart shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
This table compares Vitro Diagnostics and Vaxart’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Risk and Volatility
Vitro Diagnostics has a beta of 2.46, indicating that its stock price is 146% more volatile than the S&P 500. Comparatively, Vaxart has a beta of 0.44, indicating that its stock price is 56% less volatile than the S&P 500.
Earnings & Valuation
This table compares Vitro Diagnostics and Vaxart’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Vaxart||$4.16 million||2.66||-$18.00 million||($2.65)||-0.26|
Vitro Diagnostics has higher earnings, but lower revenue than Vaxart.
Vitro Diagnostics beats Vaxart on 5 of the 9 factors compared between the two stocks.
About Vitro Diagnostics
Vitro Diagnostics, Inc., doing business as Vitro Biopharma, focuses on the development, manufacture, and distribution of stem cell products and related tools for use in research, drug discovery, and clinical trials in the United States. Its stem cell technology includes cell lines, supporting products, and methods for generation and differentiation of stem cells into products for the treatment of diseases, such as heart disease, arthritis, multiple sclerosis, brain injury, autism, stroke, Parkinson's, and Alzheimer's diseases. The company also offers Tools for Stem Cell and Drug Discovery that provide researchers basic tools needed to advance stem cell technology, including stem cells and their derivatives; media for growth and differentiation of stem cells; and tools for measurement of stem cell quality, potency, and response to toxic agents. In addition, it offers MSC-Gro, a cell culture media product; MSC cell line for the treatment of skeletal muscular conditions, such as tendonitis, ligament injury, osteoarthritis and accelerated bone fracture healing, etc.; and testing and therapies related to endogenous stem cell activation. Further, the company provides diagnostic testing of stem cell activation and determination of stem cell functional status; and cell-based assays for discovery of novel stem cell activation agents and drugs for the treatment of osteoporosis. Vitro Diagnostics, Inc. was founded in 1986 and is based in Golden, Colorado.
Vaxart, Inc., a clinical-stage company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes tablet vaccines that are designed to protect against norovirus, seasonal influenza, and respiratory syncytial virus. It is also developing therapeutic immune-oncology vaccines for cervical cancer and dysplasia caused by human papillomavirus. The company is headquartered in South San Francisco, California.
Receive News & Ratings for Vitro Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vitro Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.